NORD and Amgen Launch Major Initiative to Tackle Rare Autoimmune Disease Diagnosis Delays

WASHINGTON, D.C. — In a significant step forward for the rare disease community, the National Organization for Rare Disorders (NORD) has announced a major collaboration with Amgen to launch a specialized Learning Collaborative through NORD’s Rare Disease Centers of Excellence Network. Supported by a sponsorship investment from Amgen, this 14-month pilot program is designed to directly address and reduce the persistent time-to-diagnosis gap that plagues millions of individuals living with rare conditions.

The nationwide initiative will bring together five to eight participating institutions from NORD’s expansive network to confront the systemic hurdles associated with diagnosing and caring for people affected by rare autoimmune diseases. By fostering inter-institutional cooperation, the partners aim to create scalable solutions that not only transform care for specific patient groups but also generate broader insights capable of benefiting the entire rare disease landscape.

Addressing Complex Autoimmune Conditions

Initially, the collaborative will focus heavily on two specific conditions: IgG4-Related Disease (IgG4-RD) and Thyroid Eye Disease (TED). Both illnesses are widely recognized within the medical community for being notoriously difficult to recognize, diagnose, and manage. Because these conditions frequently manifest symptoms that overlap with other maladies, patients often experience protracted diagnostic Odysseys, bouncing between multiple general practitioners and medical specialists before receiving an accurate evaluation.

Furthermore, managing IgG4-RD and TED requires a high degree of cross-specialty coordination, presenting ongoing hurdles for healthcare providers and patients alike. Through the upcoming pilot, clinicians hailing from participating NORD Rare Disease Centers of Excellence will collaborate closely with patients, caregivers, and disease-specific advocacy organizations. This multi-faceted team will conduct structured reviews of existing care pathways to pinpoint exactly where breakdowns occur across the healthcare continuum—from initial symptom presentation and specialist referrals to final treatment decisions and ongoing care coordination.

Leveraging diverse perspectives and deep clinical experience, the collaborative will identify concrete opportunities for operational and clinical improvement. Ultimately, the participating institutions will develop practical, evidence-based resources designed to help clinicians recognize these conditions earlier and streamline the patient journey.

A Dual Approach to Rare Disease Innovation

The structure of the initiative is intentionally designed to produce two distinct tiers of learning. First, it will deliver disease-specific approaches aimed at improving clinical recognition, screening, and care pathways explicitly for IgG4-RD and TED. Second, it will extract broader, systemic insights regarding diagnostic delays, referral bottlenecks, and multidisciplinary care coordination that can be adapted and applied to other rare diseases facing similar structural barriers.

Participating medical centers will regularly share their findings, test different operational models, and refine strategies that can eventually be adopted by other healthcare institutions across the country. This network-wide knowledge sharing ensures that the lessons learned during the 14-month pilot will have a lasting, multiplicative impact far beyond the initial cohort of participating hospitals.

“When NORD established its Rare Disease Centers of Excellence network, our vision was to bring together the expertise and resources of leading medical institutions to tackle challenges that no single institution could solve alone,” said Pam Gavin, President and Chief Executive Officer of NORD. “Amgen is committed to rare diseases and recognized the potential of this network and stepped forward to help put that vision into action. By working across institutions and alongside patients and clinicians, we have an opportunity to address challenges specific to these two diseases while developing approaches that could benefit many more rare disease communities.”

NORD and Amgen Launch Learning Collaborative to Improve Rare Disease Diagnosis and Care - National

Alignment with Broader Advocacy Goals

This new Learning Collaborative directly advances the overarching objectives of SPAARK, which stands for Strengthening Partnerships to Advance Autoimmune Rare Disease Knowledge. SPAARK is an Amgen-led alliance comprising 10 distinct professional and advocacy organizations, including NORD, unified by a shared mission to reduce the time it takes to diagnose a rare autoimmune disease by 50 percent by the year 2036.

The inclusion of patient and caregiver voices is a foundational pillar of the collaborative. For individuals and families navigating the labyrinth of rare disease care, the daily reality involves far more than securing a diagnosis.

“As a caregiver to my husband, Andy, who lives with IgG4-related disease, I know firsthand how overwhelming it can be to navigate a complex disease and find the right answers and care,” said Kat Provencher, Director of Patient Advocacy at the IgG4ward! Foundation. “For families like ours and countless others, the challenges don’t end with a diagnosis. Coordinating care across specialists and understanding the path forward can be just as difficult. What gives me hope about this collaboration is that patients and caregivers will have a voice in identifying where the system falls short and helping shape solutions that could make the journey easier for others.”

Medical leadership from Amgen echoed the urgency of addressing these systemic delays. As medical science advances therapies for complex conditions, the infrastructure supporting diagnosis and multidisciplinary care must keep pace.

“For too many people living with rare autoimmune diseases, the path to diagnosis and appropriate care is long and often filled with uncertainty,” said Paul Burton, M.D., Ph.D., senior vice president and chief medical officer at Amgen. “We believe patients deserve answers sooner. Through our collaboration with NORD and the members of SPAARK, we are bringing together diverse perspectives and expertise to address barriers to timely diagnosis, accelerate progress and help more people get the care and support they need.”

Building on a National Infrastructure

The launch of the Learning Collaborative builds upon the robust foundation laid by NORD’s Rare Disease Centers of Excellence network since its inception in 2021. Today, the network comprises 49 designated medical centers spanning more than 170 affiliated medical and research institutions nationwide. By intentionally connecting specialized clinical expertise with advanced institutional resources, the network was built specifically to bridge the historical gaps in rare disease diagnosis, research, and comprehensive care.

While Amgen is providing the sponsorship investment to make the pilot possible, NORD will maintain independent scientific and operational oversight of the collaborative. All educational resources and clinical tools developed through the initiative will be designed to support evidence-based, patient-centered care without promoting any specific medication, commercial product, or proprietary treatment approach.

About the National Organization for Rare Disorders

Founded in 1983, the National Organization for Rare Disorders (NORD®) is a leading independent, nonpartisan 501(c)(3) organization dedicated to improving the health and well-being of the more than 30 million Americans living with rare diseases. Representing more than 350 disease-specific member patient organizations and uniting 49 designated Rare Disease Centers of Excellence across more than 170 affiliated institutions, NORD continues to drive national progress in clinical care, groundbreaking research, public education, and patient advocacy.

Evan Lee Salim

Penulis aktif di HypePress yang membagikan konten inspiratif, informasi terkini, dan gaya hidup untuk generasi muda.

Artikel Bermanfaat dan Menghibur Lainnya